Company news

Orion Oyj news in 2025

Orion Oyj's news releases, calls and decks from 2025, newest first.

View company

Inside information: Orion to receive EUR 180 million milestone and updates full-year outlook for 2025

December 3, 2025

71,498 Orion Corporation A shares converted into B shares

November 27, 2025

Orion receives award for international growth from the President of the Republic of Finland

November 14, 2025

Orion Group Interim Report January–September 2025

October 28, 2025

49,164 Orion Corporation A shares converted into B shares

October 24, 2025

Orion and Abzena announce exclusive commercial license for Abzena’s antibody

October 23, 2025

Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025

October 14, 2025

Maxion Therapeutics Appoints Joel Edwards as Chief Business Officer

October 1, 2025

Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal

September 30, 2025

80,802 Orion Corporation A shares converted into B shares

September 19, 2025

337,000 Orion Corporation A shares converted into B shares

August 20, 2025

Navamedic ASA: National approvals of Flexilev® in OraFID® granted across all Nordic countries

August 13, 2025

Darolutamide receives EU approval in third indication for patients with advanced prostate cancer

July 21, 2025

Orion Group Half-Year Financial Report January–June 2025

July 18, 2025

Orion Corporation’s financial reporting and Annual General Meeting in 2026

July 18, 2025

Inside information: Orion upgrades full-year outlook for 2025

July 9, 2025

Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025

July 4, 2025

141,959 Orion Corporation A shares converted into B shares

June 23, 2025

CHMP recommends third indication for darolutamide for patients with advanced prostate cancer

June 20, 2025

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs

June 17, 2025

U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer

June 3, 2025

Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market

May 23, 2025

Orion to host Capital Markets Day today, 22 May 2025, in Helsinki

May 22, 2025

Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers

May 21, 2025

Orion Corporation: Managers’ transactions – Veli-Matti Mattila

May 2, 2025

Orion Corporation: Managers’ transactions – Maziar Mike Doustdar

May 2, 2025

Orion Corporation: Managers’ transactions – Kari Jussi Aho

May 2, 2025

Orion Corporation: Managers’ transactions – Karen Lykke Sørensen

May 2, 2025

Orion Corporation: Managers’ transactions – Hilpi Rautelin

May 2, 2025

Orion Corporation: Managers’ transactions – Henrik Stenqvist

May 2, 2025

Orion Corporation: Managers’ transactions – Eija Ronkainen

May 2, 2025

Orion Corporation: Managers’ transactions – Ari Lehtoranta

May 2, 2025

301,521 Orion Corporation A shares converted into B shares

May 2, 2025

Orion and Criceto Announce a License Agreement for APORON®, an Innovative Apomorphine Spray to Treat OFF Episodes in Parkinson’s Disease

April 25, 2025

Composition of the Nomination Committee of Orion Corporation

April 24, 2025

Orion Group Interim Report January–March 2025

April 23, 2025

Invitation to Orion’s Capital Markets Day on 22 May 2025

April 22, 2025

Calls in 2025

Decks in 2025